Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | USP2 | O75604 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19122010 | 1.00 | HTR2A (0.50) | HTR2AOPRM1CYP2D6CYP3A4USP2 | |
| Hydrochloric Acid SCHEMBL8587704 | 0.98 | HTR2A (0.48) | HTR2AOPRM1CYP2D6CYP3A4USP2 | |
| SCHEMBL27225389 | 0.88 | HTR2A (0.59) | HTR2AOPRM1CYP2D6SLC6A4SLC6A2 | |
| SCHEMBL4331091 | 0.88 | HTR2A (0.59) | HTR2AOPRM1CYP2D6SLC6A4SLC6A2 | |
| SCHEMBL27099782 | 0.88 | HTR2A (0.59) | HTR2AOPRM1CYP2D6SLC6A4SLC6A2 | |
| SCHEMBL14704743 | 0.85 | OPRM1 (0.53) | HTR2AOPRM1CYP2D6CYP3A4USP2 | |
| SCHEMBL28097789 | 0.81 | SLC6A3 (0.42) | HTR2ACYP2D6SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL21848158 | 0.81 | SLC6A2 (0.42) | HTR2ACYP2D6CYP3A4USP2ALDH1A1 | |
| SCHEMBL16488091 | 0.79 | HTR2A (0.45) | HTR2AOPRM1ALDH1A1SLC6A2SLC6A3 | |
| SCHEMBL24124002 | 0.79 | SLC6A2 (0.40) | HTR2ACYP2D6CYP3A4USP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5444062-A | Quinazolines derivatives for enhancing antitumor activity | PFIZER INC. (US) | 1995-08-22 | — | — | US | claimed |
| EP-0556310-B1 | QUINAZOLINES DERIVATIVES FOR ENHANCING ANTITUMOR ACTIVITY | PFIZER (US) | 1995-07-05 | — | — | EP | claimed |
| EP-0556310-A1 | QUINAZOLINES DERIVATIVES FOR ENHANCING ANTITUMOR ACTIVITY. | PFIZER (US) | 1993-08-25 | — | — | EP | claimed |
| WO-1992007844-A1 | QUINAZOLINES DERIVATIVES FOR ENHANCING ANTITUMOR ACTIVITY | PFIZER INC. (US) | 1992-05-14 | — | — | WO | claimed |
| EP-4146220-B1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250388574-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12319691-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | AMGEN INC. (US) | 2025-06-03 | — | — | US | disclosed |
| US-12252489-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | AMGEN INC. (US) | 2025-03-18 | — | — | US | disclosed |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | INITIAL THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| WO-2024226875-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR ATTENUATION OF MAMMALIAN TRANSLATION OF C-MYC OR N-MYC PROTEINS OF THE MYC PROTO-ONCOGENE FAMILY OF BHLH TRANSCRIPTION FACTORS | INITIAL THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| US-20240190863-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. | 2024-06-13 | — | — | US | disclosed |
| US-20240124446-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. | 2024-04-18 | — | — | US | disclosed |
| CN-1173921-A | Methods for prodn. ef large catalogued chemical libraries | PANLABS INC (US) | 1998-02-18 | — | — | CN | disclosed |
| EP-0808303-A1 | 5-(4-SUBST.-PIPERIDINYL-1)-3-ARYL-PENTANOIC ACID DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONIST | ZENECA LIMITED (GB) | 1997-11-26 | — | — | EP | disclosed |
| WO-1996024582-A1 | 5-(4-SUBST.-PIPERIDINYL-1)-3-ARYL-PENTANOIC ACID DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONIST | ZENECA LIMITED (GB) | 1996-08-15 | — | — | WO | disclosed |
| WO-1996002250-A1 | HALOPERIDOL ANALOGS AND THE USE THEREOF | ACEA PHARMACEUTICALS INC. (US) | 1996-02-01 | — | — | WO | disclosed |
| US-5444062-A | Quinazolines derivatives for enhancing antitumor activity | PFIZER INC. (US) | 1995-08-22 | — | — | US | disclosed |
| EP-0556310-B1 | QUINAZOLINES DERIVATIVES FOR ENHANCING ANTITUMOR ACTIVITY | PFIZER (US) | 1995-07-05 | — | — | EP | disclosed |
| EP-0556310-A1 | QUINAZOLINES DERIVATIVES FOR ENHANCING ANTITUMOR ACTIVITY. | PFIZER (US) | 1993-08-25 | — | — | EP | disclosed |
| WO-1992007844-A1 | QUINAZOLINES DERIVATIVES FOR ENHANCING ANTITUMOR ACTIVITY | PFIZER INC. (US) | 1992-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12252489-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | MSR1, FPR2, CD14 | HTR2A 408/4885OPRM1 605/4885CYP2D6 1500/4885 |
| US-20240190863-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | HTR2A 408/4885OPRM1 605/4885CYP2D6 1500/4885 |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | MYCBP, MYC, MYCBP2 | HTR2A 4445/4885OPRM1 4085/4885CYP2D6 3964/4885 |
| US-12319691-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | MSR1, FPR2, CD14 | HTR2A 279/4885OPRM1 562/4885CYP2D6 1342/4885 |
| US-20240124446-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | HTR2A 279/4885OPRM1 562/4885CYP2D6 1342/4885 |
| US-20250388574-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FCER2, HAVCR2 | HTR2A 569/4885OPRM1 245/4885CYP2D6 1399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.